Total debt more than doubled from $30.7B to $72.6B over ten quarters, lifting debt-to-equity from 0.10 to 0.19 and goodwill from $4.2B to $13.0B, while the current ratio declined from 2.55 to 1.93, suggesting an acquisition-driven capital structure shift that warrants closer examination of impairment risk.
Dr. Reddy's Laboratories Limited (RDY) balance sheet — 26-year assets, liabilities & shareholders' equity history
| Metric | TTM | Mar'26 | Mar'25 | Mar'24 | Mar'23 | Mar'22 | Mar'21 | Mar'20 | Mar'19 | Mar'18 | Mar'17 | Mar'16 | Mar'15 | Mar'14 | Mar'13 | Mar'12 | Mar'11 | Mar'10 | Mar'09 | Mar'08 | Mar'07 | Mar'06 | Mar'05 | Mar'04 | Mar'03 | Mar'02 | Mar'01 |
|---|
| Total Current Assets | 298.88B | 296B | 250.11B | 248.05B | 204.25B | 181.86B | 2.03B | 1.72B | 114.5B | 109.64B | 100.38B | 119.69B | 119.84B | 103.75B | 857.13B | 69.95B | 47.59B | 42.06B | 39.01B | 34.62B | 37.56B | 20.14B | 18.35B | 15.7B | 15.08B | 11.87B | 5.29B |
| Cash & Short-Term Investments | 76.58B | 86.08B | 57.91B | 81.47B | 61.8B | 44.37B | 472.87M | 340.25M | 24.76B | 20.97B | 18.14B | 39.95B | 39.65B | 33.53B | 220.99B | 18.15B | 5.76B | 10.76B | 6.13B | 12.15B | 18.04B | 3.74B | 9.6B | 6.93B | 7.25B | 5.1B | 477.24M |
| Cash Only | 13.35B | 15.06B | 14.65B | 7.11B | 5.78B | 14.85B | 202.82M | 27.14M | 2.23B | 2.64B | 18.14B | 39.95B | 39.65B | 33.53B | 51.36B | 18.15B | 5.73B | 6.58B | 5.6B | 7.4B | 18.02B | 3.72B | 9.29B | 4.39B | 7.25B | 5.1B | 477.24M |
| Short-Term Investments | 63.22B | 71.01B | 43.25B | 74.36B | 56.02B | 29.51B | 270.04M | 313.11M | 22.53B | 18.33B | 0 | 0 | 0 | 0 | 169.63B | 0 | 33M | 4.17B | 530M | 4.75B | 15.38M | 14.75M | 310.87M | 2.54B | 0 | 0 | 0 |
| Accounts Receivable | 101.84B | 99.22B | 109.79B | 95.34B | 83.2B | 80.27B | 843.66M | 816.3M | 46.63B | 50.2B | 45.74B | 48.6B | 48.59B | 41.02B | 38.55B | 30.04B | 22.44B | 15.79B | 19.66B | 6.9B | 7.68B | 4.81B | 3.59B | 3.76B | 3.61B | 3.83B | 2.39B |
| Days Sales Outstanding | 123.84 | 102.45 | 123.1 | 124.65 | 123.51 | 136.66 | 120.49 | 1.71 | 110.63 | 129.01 | 118.56 | 114.67 | 119.69 | 113.29 | 121.02 | 113.33 | 109.66 | 82.02 | 103.33 | 50.34 | 42.97 | 72.22 | 67.24 | 68.21 | 73.12 | 84.1 | 79.92 |
| Inventory | 81.54B | 75.02B | 71.08B | 63.55B | 48.67B | 50.88B | 621.11M | 463.52M | 33.58B | 29.09B | 28.53B | 25.58B | 25.53B | 23.99B | 216B | 19.35B | 16.06B | 13.37B | 13.23B | 11.13B | 7.56B | 6.91B | 3.5B | 3.04B | 2.77B | 2.19B | 1.91B |
| Days Inventory Outstanding | 172.22 | 164 | 192.04 | 200.74 | 166.75 | 184.71 | 180.23 | 2.1 | 174.04 | 161.55 | 166.73 | 149.55 | 148.41 | 155.35 | 1.42K | 162.63 | 170.25 | 143.81 | 146.55 | 165.2 | 80.48 | 202.66 | 136.09 | 118.4 | 129.51 | 116.6 | 122.14 |
| Other Current Assets | 38.92B | 35.69B | 4.56B | 2.94B | 6.41B | 5.2B | 74.4M | 90.68M | 15.35B | 18.21B | 14.93B | 12.17B | 13.9B | 12.65B | 2.94B | 1.12B | 2.17B | 2.44B | 0 | 0 | 4.41B | 4.68B | 1.67B | 1.72B | 1.26B | 744.69M | 504.57M |
| Total Non-Current Assets | 278.12B | 271.88B | 242.88B | 139.47B | 117.6B | 110.97B | 1.6B | 1.35B | 110.93B | 115.96B | 119.45B | 87.96B | 74.92B | 66.48B | 566.56B | 49.52B | 47.41B | 38.27B | 44.78B | 50.82B | 48.57B | 48.8B | 10.94B | 10.97B | 7.94B | 7.08B | 6.55B |
| Property, Plant & Equipment | 115.6B | 113.63B | 97.76B | 76.89B | 66.46B | 62.17B | 781.13M | 691.75M | 54.09B | 57.87B | 57.16B | 53.96B | 48.09B | 44.42B | 378.14B | 33.25B | 29.64B | 22.46B | 20.88B | 16.77B | 12.46B | 9.11B | 7.06B | 6.34B | 4.82B | 3.79B | 3.23B |
| Fixed Asset Turnover | 2.88x | 3.11x | 3.33x | 3.63x | 3.70x | 3.45x | 3.27x | 252.40x | 2.84x | 2.45x | 2.46x | 2.87x | 3.08x | 2.98x | 0.31x | 2.91x | 2.52x | 3.13x | 3.33x | 2.98x | 5.24x | 2.67x | 2.76x | 3.17x | 3.74x | 4.38x | 3.38x |
| Goodwill | 13.04B | 12.64B | 11.81B | 4.25B | 4.25B | 4.42B | 62.48M | 52.79M | 3.9B | 3.94B | 3.75B | 3.85B | 3.38B | 3.43B | 31.93B | 2.21B | 2.18B | 2.17B | 7.3B | 16.98B | 15.58B | 16.68B | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 104.62B | 102.98B | 96.8B | 36.95B | 30.85B | 27.25B | 487.57M | 365.61M | 44.37B | 44.66B | 44.92B | 20.8B | 13.05B | 11.27B | 108.28B | 11.32B | 13.07B | 11.8B | 14.88B | 16.62B | 18.93B | 17.08B | 2.59B | 2.67B | 2.86B | 2.86B | 2.88B |
| Long-Term Investments | 58.24B | 16.04B | 15.2B | 5.25B | 5.36B | 7.99B | 115.59M | 63.82M | 3.34B | 4.65B | 6.84B | 3.3B | 3.85B | 806M | 6.81B | 368M | 313M | 310M | 262M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5.24B | 4.59B | 2.79B | 5.35B | 3.49B | 948M | 11.41M | 11.16M | 1.06B | 1.2B | 1.19B | 1.06B | 762M | 495M | 37.74B | 417M | 276M | 243M | 200M | 457.88M | 1.6B | 5.94B | 1.29B | 1.96B | 265.97M | 422.61M | 440.46M |
| Total Assets | 577B | 567.88B | 492.99B | 387.52B | 321.85B | 292.83B | 3.63B | 3.07B | 225.43B | 225.6B | 219.82B | 207.65B | 194.76B | 170.22B | 1.42T | 119.48B | 95B | 80.33B | 83.79B | 85.45B | 86.12B | 68.95B | 29.29B | 26.68B | 23.03B | 18.95B | 11.84B |
| Asset Turnover | 0.58x | 0.62x | 0.66x | 0.72x | 0.76x | 0.73x | 0.70x | 56.88x | 0.68x | 0.63x | 0.64x | 0.75x | 0.76x | 0.78x | 0.08x | 0.81x | 0.79x | 0.87x | 0.83x | 0.59x | 0.76x | 0.35x | 0.66x | 0.75x | 0.78x | 0.88x | 0.92x |
| Asset Growth % | 49.39% | 15.19% | 27.22% | 20.4% | 9.91% | 7964.18% | 18.28% | -98.64% | -0.08% | 2.63% | 5.86% | 6.62% | 14.42% | -88.04% | 1091.6% | 25.76% | 18.27% | -4.13% | -1.93% | -0.79% | 24.91% | 135.4% | 9.79% | 15.86% | 21.53% | 60.02% | - |
| Total Current Liabilities | 155.17B | 164.25B | 130.39B | 96.04B | 85.84B | 94.02B | 1.14B | 962.5M | 59.7B | 69.69B | 85B | 64.65B | 63.99B | 54.06B | 536.46B | 43.46B | 41.02B | 29.02B | 26.55B | 19.39B | 18.58B | 18.79B | 7.58B | 4.58B | 3.09B | 2.36B | 4.5B |
| Accounts Payable | 36.24B | 32.75B | 20.05B | 21.55B | 17.86B | 15.97B | 173.65M | 142.03M | 10.3B | 9.21B | 0 | 0 | 0 | 0 | 0 | 9.5B | 8.48B | 9.32B | 5.99B | 5.43B | 4.77B | 3.65B | 1.42B | 2.18B | 1.68B | 1.12B | 681.87M |
| Days Payables Outstanding | 80.26 | 71.6 | 54.17 | 68.06 | 61.18 | 57.97 | 50.39 | 0.64 | 53.37 | 51.14 | - | - | - | - | - | 79.85 | 89.9 | 100.26 | 66.34 | 80.53 | 50.72 | 106.97 | 55.05 | 84.91 | 78.47 | 59.65 | 43.55 |
| Short-Term Debt | 60.86B | 63.85B | 38.05B | 12.72B | 11.19B | 27.08B | 328.38M | 274.92M | 16.32B | 25.56B | 43.74B | 22.72B | 28.82B | 23.9B | 24.05B | 15.84B | 18.3B | 9.31B | 9.57B | 6.68B | 3.67B | 10.08B | 2.8B | 474.27M | 289.29M | 105.64M | 2.94B |
| Deferred Revenue (Current) | 3.52B | 0 | 1.98B | 1.44B | 1.98B | 2.58B | 27.81M | 25.25M | 1.35B | 982M | 819M | 659M | 1.06B | 678M | 553M | 39M | 503M | 29M | 1.93B | 587.38M | 557.79M | 173.75M | 236.93M | 152.22B | 166.51B | 695.29M | 382.02M |
| Other Current Liabilities | 55.25B | 63.43B | 13.52B | 11.42B | 9.19B | 6.76B | 515.05M | 447.37M | 9.21B | 11.04B | 8.91B | 10.91B | 24.43B | 7.97B | 487.5B | 6.04B | 5.36B | 2.49B | 10.37B | 3.13B | 6.17B | 1.8B | 988.95M | 675.53M | 357.01M | 435.81M | 494.09M |
| Current Ratio | 1.93x | 1.80x | 1.92x | 2.58x | 2.38x | 1.93x | 1.78x | 1.79x | 1.92x | 1.57x | 1.18x | 1.85x | 1.87x | 1.92x | 1.60x | 1.61x | 1.16x | 1.45x | 1.47x | 1.79x | 2.02x | 1.07x | 2.42x | 3.43x | 4.87x | 5.03x | 1.18x |
| Quick Ratio | 1.40x | 1.35x | 1.37x | 1.92x | 1.81x | 1.39x | 1.23x | 1.31x | 1.36x | 1.16x | 0.85x | 1.46x | 1.47x | 1.48x | 1.20x | 1.16x | 0.77x | 0.99x | 0.97x | 1.21x | 1.61x | 0.70x | 1.96x | 2.77x | 3.98x | 4.10x | 0.75x |
| Cash Conversion Cycle | 215.81 | 194.86 | 260.97 | 257.33 | 229.08 | 263.39 | 250.33 | 3.16 | 231.3 | 239.42 | - | - | - | - | - | 196.11 | 190.01 | 125.57 | 183.54 | 135 | 72.74 | 167.92 | 148.29 | 101.69 | 124.15 | 141.05 | 158.51 |
| Total Non-Current Liabilities | 30.75B | 30.7B | 25.43B | 10.93B | 5.02B | 8.29B | 123.62M | 58.68M | 25.53B | 29.45B | 10.78B | 14.67B | 19.46B | 25.36B | 156.18B | 18.57B | 8B | 8.39B | 15.19B | 18.99B | 25.86B | 27.82B | 753.28M | 1.02B | 1.15B | 1.15B | 2.11B |
| Long-Term Debt | 11.74B | 11.96B | 3.8B | 3.8B | 0 | 3.8B | 51.97M | 0 | 21.45B | 24.46B | 4.85B | 9.94B | 14.31B | 19.79B | 11.83B | 16.07B | 5.32B | 5.38B | 0 | 12.86B | 17.91B | 20.99B | 25.15M | 31.15M | 40.81M | 46.97M | 999.73M |
| Capital Lease Obligations | 23.49B | 0 | 4.06B | 2.19B | 1.28B | 1.95B | 34.18M | 17.24M | 552M | 630M | 597M | 747M | 775M | 947M | 796M | 260M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 62.5B | 15.26B | 14.11B | 909M | 833M | 60M | 4.62M | 3.64M | 610M | 730M | 1.2B | 767M | 1.78B | 2.74B | 1.98B | 1.13B | 2.02B | 2.72B | 4.67B | 5.64B | 7.57B | 6.36B | 551.79M | 572.8M | 698.25M | 657.18M | 861.73M |
| Other Non-Current Liabilities | 2.75B | 3.48B | 2.3B | 2.84B | 1.35B | 882M | 11.9M | 11.95M | 918M | 4.36B | 5.33B | 3.98B | 4.38B | 4.62B | 143.56B | 1.11B | 662M | 288M | 10.48B | 458M | 284.33M | 412.97M | 118.08M | 412.54M | 414.03M | 443.42M | 244.95M |
| Total Liabilities | 185.92B | 194.95B | 155.82B | 106.97B | 90.86B | 102.3B | 1.26B | 1.02B | 85.23B | 99.14B | 95.78B | 79.31B | 83.46B | 79.42B | 692.64B | 62.03B | 49.02B | 37.41B | 41.75B | 38.38B | 44.44B | 46.62B | 8.34B | 5.59B | 4.25B | 3.51B | 6.6B |
| Total Debt | 72.6B | 75.81B | 46.77B | 20.02B | 13.47B | 33.84B | 414.53M | 292.16M | 38.38B | 50.71B | 49.19B | 33.51B | 43.13B | 44.74B | 367.6B | 32.21B | 23.62B | 14.7B | 19.7B | 19.54B | 24.81B | 31.08B | 2.83B | 505.42M | 330.09M | 152.61M | 3.94B |
| Net Debt | 59.25B | 60.75B | 32.11B | 12.91B | 7.69B | 18.99B | 211.71M | 265.02M | 36.15B | 48.08B | 31.05B | -6.44B | 3.47B | 11.21B | 316.23B | 14.06B | 17.89B | 8.11B | 14.11B | 12.14B | 6.79B | 27.35B | -6.46B | -3.88B | -6.92B | -4.95B | 3.46B |
| Debt / Equity | 0.19x | 0.20x | 0.14x | 0.07x | 0.06x | 0.18x | 0.18x | 0.14x | 0.27x | 0.40x | 0.40x | 0.26x | 0.39x | 0.49x | 0.50x | 0.56x | 0.51x | 0.34x | 0.47x | 0.42x | 0.60x | 1.39x | 0.13x | 0.02x | 0.02x | 0.01x | 0.75x |
| Debt / EBITDA | 1.42x | 1.07x | 0.53x | 0.24x | 0.19x | 0.82x | 0.03x | 0.01x | 1.16x | 2.15x | 1.99x | 0.84x | 1.25x | 1.35x | 13.79x | 1.37x | 1.41x | 2.38x | 20.10x | 2.04x | 1.74x | 10.30x | 3.00x | 0.16x | 0.08x | 0.03x | 1.66x |
| Net Debt / EBITDA | 1.16x | 0.86x | 0.36x | 0.16x | 0.11x | 0.46x | 0.02x | 0.01x | 1.09x | 2.03x | 1.25x | -0.16x | 0.10x | 0.34x | 11.86x | 0.60x | 1.07x | 1.32x | 14.39x | 1.27x | 0.48x | 9.07x | -6.85x | -1.21x | -1.59x | -0.82x | 1.46x |
| Interest Coverage | 7.16x | 15.66x | 28.14x | 43.00x | 43.27x | 34.71x | 0.37x | 2114.41x | 26.25x | 19.20x | 24.11x | 33.86x | 26.79x | 21.88x | 22.29x | 18.31x | 35.01x | 6.52x | -1.40x | 3.65x | - | - | - | - | - | - | - |
| Total Equity | 391.08B | 372.92B | 337.17B | 280.55B | 230.99B | 190.53B | 2.37B | 2.05B | 140.2B | 126.46B | 124.04B | 128.34B | 111.3B | 90.8B | 731.04B | 57.44B | 45.99B | 42.91B | 42.05B | 47.07B | 41.69B | 22.33B | 20.95B | 21.08B | 18.78B | 15.44B | 5.24B |
| Equity Growth % | 44.79% | 10.61% | 20.18% | 21.45% | 21.24% | 7949.22% | 15.54% | -98.54% | 10.86% | 1.95% | -3.34% | 15.3% | 22.58% | -87.58% | 1172.62% | 24.91% | 7.17% | 2.07% | -10.67% | 12.9% | 86.69% | 6.57% | -0.63% | 12.29% | 21.61% | 194.81% | - |
| Book Value per Share | 469.29 | 447.55 | 404.13 | 336.58 | 277.66 | 229.08 | 2.85 | 2.47 | 168.71 | 152.19 | 148.56 | 150.04 | 130.23 | 106.39 | 857.87 | 67.51 | 54.12 | 50.60 | 49.95 | 55.80 | 52.35 | 29.11 | 27.37 | 27.54 | 24.54 | 20.28 | 8.29 |
| Total Shareholders' Equity | 387.87B | 369.6B | 333.39B | 280.55B | 230.99B | 190.53B | 2.37B | 2.05B | 140.2B | 126.46B | 124.04B | 128.34B | 111.3B | 90.8B | 730.85B | 57.44B | 45.99B | 42.91B | 42.05B | 47.07B | 41.68B | 22.33B | 20.95B | 21.08B | 18.78B | 15.44B | 5.22B |
| Common Stock | 838.66M | 818.47M | 834M | 834M | 833M | 832M | 11.38M | 10.98M | 830M | 830M | 829M | 853M | 852M | 851M | 8.49B | 848M | 846M | 844M | 842M | 840.88M | 841.53M | 384.46M | 382.58M | 383.43M | 381.47M | 382.17M | 314.75M |
| Retained Earnings | 360.58B | 345.02B | 315.79B | 265.26B | 215.59B | 175.71B | 2.13B | 1.91B | 128.65B | 113.86B | 108.22B | 99.55B | 83.64B | 65.05B | 44.81B | 31.6B | 20.39B | 18.04B | 18.3B | 24.03B | 20.14B | 11.23B | 10.01B | 10.25B | 8.3B | 4.98B | 624.83M |
| Treasury Stock | -1.49B | -1.78B | -2.26B | -991M | -1.27B | -1.6B | -26.9M | -13.3M | -535M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.88M | 0 | 0 | -10.09B | 0 | 0 | 0 | 0 |
| Accumulated OCI | 16.42B | 10.5B | 3.98B | 653M | 886M | 755M | 127.02M | 32M | 3.04B | 3.98B | 7.8B | 5.33B | 4.63B | 3.35B | 722.36B | 865M | 0 | 0 | 2.17B | 2.16B | 740.48M | 425.76M | 472.1M | 338.66M | 41.33M | 3.36M | 1.26M |
| Minority Interest | 3.2B | 3.33B | 3.78B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 192M | 0 | 0 | 0 | 0 | 0 | 10.5M | 0 | 0 | 0 | 0 | 0 | 15.92M |
Quick answers to the most common questions about buying RDY stock.
As of 2026, Dr. Reddy's Laboratories Limited (RDY) had total assets of $567.88B including $296.00B in current assets.
Dr. Reddy's Laboratories Limited (RDY) carries total debt of $75.81B, offset by $86.08B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Dr. Reddy's Laboratories Limited (RDY) has total shareholders' equity (book value) of $369.60B ($447.55 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Dr. Reddy's Laboratories Limited (RDY) reported a current ratio of 1.80x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Goodwill impairment amid rising leverage
Debt Doubling Amid Cash Flow Stress
Total debt has more than doubled from $30.7B in 2025Q1 to $72.6B by 2027Q2, lifting the debt-to-equity ratio from 0.10 to 0.19. The concurrent goodwill surge suggests leverage was deployed for acquisitions rather than necessity, though deteriorating operating cash flow complicates repayment capacity.
The 136% increase in total debt from $30.7B to $72.6B coincides closely with the goodwill revaluation from $4.2B to $11.8B, strongly suggesting acquisition-related borrowing rather than operational financing. However, prior cash flow analysis documented a collapse in operating cash flow to negative $927M in 2027Q1 and a cumulative OCF/NI ratio of approximately 0.79 over the period, meaning the company's ability to service this elevated debt load from internal cash generation has weakened materially even as the headline leverage ratio of 0.19 remains low by industry standards. The concern is not nominal leverage but the divergence between rising obligations and a cash generation profile that has turned negative in recent quarters. Investors should monitor whether debt continues to climb without a corresponding recovery in operating cash flow, as the current trajectory could shift leverage from strategic to necessity-driven.
Cash Volatility Thins Liquidity Buffer
Dr. Reddy's current ratio declined from 2.55 to 1.93 over ten quarters, while cash reserves swung between $4.9B and $18.7B before settling at $13.4B in 2027Q2. This pattern, combined with documented working capital consumption, suggests a structurally thinner liquidity buffer against near-term operational shocks.
The current ratio compression from 2.55 to 1.93 reflects a structural shift rather than a temporary fluctuation, as it has trended consistently downward even as absolute cash balances fluctuated with working capital timing. With working capital consuming $21.9B across 2027Q1 and 2027Q2 per the cash flow analysis, the liquidity position appears increasingly dependent on the timing of receipts and inventory liquidation rather than a stable cash reserve. The $13.4B cash position at 2027Q2 represents only approximately 18% of total debt, suggesting limited flexibility if operational cash generation continues to disappoint. While the current ratio above 1.9 remains above distress levels, the trajectory indicates that the buffer is eroding in tandem with deteriorating free cash flow, warranting close monitoring of near-term working capital management.
Acquisition-Driven Asset Expansion Elevates Risk
A dramatic goodwill revaluation from $4.2B to $11.8B between 2025Q1 and 2025Q2 signals a transformative acquisition, while net PPE expanded 44% to $115.6B, indicating concurrent organic capital investment that has materially increased the asset base's sensitivity to pricing pressure and impairment risk.
The goodwill step-up is the single most significant structural change in the asset base, indicating a major acquisition whose integration outcomes are not yet visible in the deteriorating operating margins documented in the income statement analysis. Meanwhile, PPE growth of 44% from $80.3B to $115.6B suggests aggressive capacity expansion, but with gross margins compressing 830 basis points and revenue contracting, the return on these invested assets appears increasingly questionable. The asset mix is becoming more capital-intensive at precisely the moment when pricing power is eroding, which could result in future impairment charges if the acquired business or newly expanded capacity fails to generate adequate returns. This structural shift in asset composition deserves closer scrutiny than the headline asset growth figure suggests.
Leverage Shift Outpaces Equity Growth
Total assets expanded 39% from $415.3B to $577.0B over ten quarters, yet debt grew 136% against equity growth of only 32%, indicating the balance sheet's financing mix has shifted materially toward leverage even as reported profitability margins have compressed sharply.
While the headline balance sheet metrics appear healthy—assets up 39%, equity up 32%, retained earnings compounding from $279.3B to $360.6B—the underlying trajectory reveals a growing reliance on debt financing. Debt's 136% growth far outpaces the 32% equity expansion, meaning each incremental dollar of assets is increasingly debt-financed rather than equity-funded. Combined with the documented free cash flow swing from $10.8B in 2025Q4 to negative $4.6B in 2027Q1, this trajectory suggests the balance sheet's resilience is being gradually sacrificed to fund growth that has yet to produce commensurate cash returns. The retained earnings accumulation remains a positive signal of underlying profitability, but its pace is unlikely to offset the leverage shift if cash flow recovery remains elusive.
Goodwill Carrying Value Warrants Skepticism
Goodwill now represents $13.0B of total assets, and with operating margins falling from 23.4% to 13.7% and revenue contracting, the risk of impairment thresholds being approached is elevated, which could materially compress the $387.9B equity base reported in 2027Q2.
The $13.0B in goodwill represents a contingent impairment risk that headline balance sheet metrics may understate. Given the prior income statement analysis showing operating margin decline from 23.4% to 13.7% and revenue contraction in the most recent quarter, the acquired business may not be generating returns sufficient to justify its carrying value. A write-down would directly reduce the reported $387.9B equity base and could push the effective debt-to-equity ratio materially above the reported 0.19, revealing a more leveraged balance sheet than the current figures suggest. This dynamic is compounded by the earnings quality concerns identified in prior analysis, where the cumulative operating cash flow shortfall of approximately $23.7B relative to net income suggests that the accounting profits supporting goodwill valuation may not be fully cash-backed. Investors should monitor impairment disclosures closely in upcoming filings.